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IMMUNOGENICITY OF INTRADERMAL TRIVALENT INFLUENZA 
VACCINE WITH TOPICAL IMIQUIMOD: A DOUBLEBLIND RANDOMISED 
CONTROLLED TRIAL 
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BACKGROUND: Imiquimod, a synthetic toll-like receptor 7-agonist enhanced 
immunogenicity of influenza vaccine in a mouse model. We hypothesised that topical 
imiquimod before intradermal trivalent influenza vaccination (TIV) will produce similar 
effect in human. 
 
METHODS: We performed a prospective 1-year follow-up double-blind randomised 
controlled trial on adults with co-morbidities. Subjects were randomised to one of the 
three vaccinations: topical 5% 250 mg imiquimod ointment followed by intradermal TIV 
(IntanzaR15, Sanofi-Pasteur, France), or topical aqueous-cream followed by intradermal 
TIV, or topical aqueous-cream followed by intramuscular TIV (VaxigripR, Sanofi-
Pasteur, France). Patients and investigators were blinded to the type of topical treatment 
applied. Haemagglutination inhibition (HI) and microneutralisation antibody titres were 
measured. Primary outcome was day-7 seroconversion rate. 
 
RESULTS: A total of 91 recruited subjects completed the study. The median age was 73 
years. On day 7, 27/30 (90%) patients who received imiquimod and intradermal TIV 
achieved seroconversion against the H1N1 strain by HI, compared to 4/30 (13.3%) who 
received aqueous-cream and intramuscular TIV (P<0.001) and 12/31 (38.7%) who 
received aqueous-cream and intradermal TIV (P<0.001). The seroconversion, 
seroprotection, and geometric mean titre fold increase were met in all three strains in the 
imiquimod and intradermal TIV group 2 weeks earlier, and the better seroconversion rate 
was sustained from day 7 to year 1 (P≤0.001). The better immunogenicity was associated 
with less hospitalisation for influenza or pneumonia (P<0.05). All adverse reactions were 
self-limited. 
 
CONCLUSIONS: Pretreatment with topical imiquimod significantly expedited, 
augmented, and prolonged the immunogenicity of influenza vaccination. This strategy for 
influenza immunisation should be considered in the elderly population. 
 
Note: The study was published in the Clinical Infectious Diseases: Hung IF, Zhang AJ, 
To KK, et al. Immunogenicity of intradermal trivalent influenza vaccine with topical 
imiquimod: a double blind randomized controlled trial. Clin Infect Dis 2014;59:1246-55. 
